Skip to main content
. 2017 Mar 28;2017(3):CD011343. doi: 10.1002/14651858.CD011343.pub2

NCT03035058.

Trial name or title NCT03035058.
Methods Randomised, double‐blind, placebo‐controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Vedolizumab vs placebo.
Outcomes No outcomes of interest for this review.
Starting date February 2017.
Contact information medicalinformation@tpna.com
Notes  

vs = versus